Evaxion A/S announced it will expand the use of its proprietary AI-Immunology? platform to also discover and develop new treatments for autoimmune diseases. Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
The expansion leverages the unique scalability of AI-Immunology? and will increase the pool of diseases for which the company can decode the immune system and potentially discover and develop new treatments. In turn, this will improve the quantity and quality of new programs within pipeline, potentially available for partnership.
Autoimmune diseases are characterized by high unmet medical need and offer significant partnership potential across all stages of drug development. Evaxion plans to expand and train AI-Immunology? to be applicable to autoimmune diseases during the second half of 2026.
Specifically, the AI-Immunology? platform potentially allows for development of precision treatments targeting underlying disease mechanisms, in contrast to current treatment approaches that primarily address symptoms. The related work on the autoimmune disease application development is already included in Evaxion?s cashflow outlook and does not impact our cash runway, which still extends to the second half of 2027. The expansion to autoimmune diseases represents a new strategic milestone for Evaxion in addition to other milestones for 2026 as outlined below.
These reflect continued execution of strategy of creating value from both platform and pipeline assets through partnerships. Milestone Target: EVX-01 Additional biomarker and immunogenicity data First Half; AI-Immunology? New application for autoimmune diseases Second Half; EVX-01 Three-year phase 2 clinical efficacy data Second Half; EVX-04 Regulatory filing for phase 1 trial Second Half; EVX-B4 Design and preclinical validation of antigens Second Half.
